At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Zeng Hao, Professor of Urology at West China Hospital, Sichuan University, delivered a talk on “The Current State of Renal Oncology in China”.
Dr. Zeng highlighted China’s leading share of kidney cancer cases globally, noting that nearly half of new diagnoses and deaths occur in Asia due to its large population base. While five-year survival in top Chinese cancer centers approaches 75%, outcomes across the country are uneven, with patients in rural or smaller cities often diagnosed at later stages and facing poorer prognoses. Early detection and equitable access remain critical priorities.
He described rapid advances in imaging, AI-driven diagnostic models, and precision pathology that are improving pre-surgical planning and molecular classification of RCC subtypes. Surgical techniques have evolved from open procedures to laparoscopic and robotic approaches, while systemic therapy is expanding with IO/TKI combinations and domestic drug development. Still, access to cutting-edge therapies varies widely, and Dr. Zeng emphasized the importance of reducing regional disparities, strengthening multidisciplinary care, and ensuring affordable availability of new treatments across China.
Join us in this conversation.